Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database

Kidney cancer is the third most common genitourinary malignancy, with an estimated 65,340 new diagnoses and 14,970 deaths in 2018 [1]. The vast majority of kidney cancers are renal cell carcinoma (RCC), accounting for over 90% of renal parenchymal tumors [2]. RCC is associated with significant morbidity and mortality, and an especially poor prognosis when there is lymph node (LN) involvement. For example, numerous studies have identified both clinical and pathologic lymphadenopathy as independent adverse prognostic factors for cancer-specific survival (CSS) and all-cause mortality (ACM) [3].

Source: Urologic Oncology: Seminars and Original Investigations - November 13, 2018 Category: Urology & Nephrology Authors: Nicholas J. Farber, Zorimar Rivera-N úñez, Sinae Kim, Brian Shinder, Kushan Radadia, Joshua Sterling, Parth K. Modi, Sharad Goyal, Rahul Parikh, Tina M. Mayer, Robert E. Weiss, Isaac Y. Kim, Sammy E. Elsamra, Thomas L. Jang, Eric A. Singer Tags: Original Article Source Type: research